January 23, 2017 – At the annual meeting of Radiological Society of North America, 3D Systems announced a new D2P (DICOM ...

The U.S. Food and Drug Administration (FDA) announced last week it is providing information and recommendations regarding the Zoll LifeVest 4000 due to concerns that the device may fail to deliver treatment to the patient if the device is not replaced soon after displaying "Call for service: Device has a problem that may require service. Call Zoll for service, Message Code 102." Failure to contact Zoll and immediately replace the device after Message Code 102 appears on the device screen may result in serious patient harm or death of the patient because the device may fail to deliver therapy appropriately when needed.

Ligand Pharmaceuticals Inc. announced initiation of a program to develop contrast agents with reduced renal toxicity. Through this new, internally-funded program, Ligand intends to advance products toward proof-of-concept, followed by selling or out-licensing them for further development and commercialization. The program will leverage Ligand’s patented Captisol technology, as well as data and intellectual property obtained through its acquisition of Verrow Pharmaceuticals, a privately-held Lenexa, Kansas-based medical invention company that Ligand acquired in January 2018 for $2 million in cash plus earnouts.

The U.S. Food and Drug Administration (FDA) announced that International Laboratories LLC is voluntarily recalling Lot# 117099A of Clopidogrel Tablets, USP 75 mg, packaged in bottles of 30 tablets, to the consumer level due to mislabeling. The product is labeled as Clopidogrel Tablets USP, 75 mg but may contain Clopidogrel 75mg or Simvastatin Tablets USP 10 mg.

January 18, 2018 – West Hills Hospital & Medical Center, a full-service acute care facility, announces the first ...

Secant Group, in partnership with its sister company SanaVita Medical, announced new technology to advance cardiovascular regenerative medicine with the development of a synthetic, small-bore vessel that encourages endogenous regeneration and new vessel formation. The technology is based on the company’s textile forming capabilities that can produce a hollow lumen construct infused with Secant’s proprietary Regenerez bioresorbable polymer technology. The new small-bore vessel supports the regeneration of new vascular tissue structures without the need for cell seeding or biologic growth promoters.